NP49425 Generic and Biosimilar Transition Medicines

View buyer

Estimated value

goods

Awarded value

Suppliers

75

Lots

10

10 awarded

Published

19 Dec 2025

Total lots

10

Awarded

10

0 pending

Estimated total

£235.0m

Awarded total

Lot 1cancelled

Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)

Award value

Start

01 Feb 2026

End

28 Feb 2027

Estimated

£100.0m

CPV

33600000
Lot 2cancelled

Cytokine Modulators (Omalizumab)

Award value

Start

31 Mar 2026

End

28 Feb 2027

Estimated

£15.6m

CPV

33600000
Lot 3cancelled

Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines

Award value

Start

01 Feb 2026

End

31 Jul 2027

Estimated

£26.2m

CPV

33600000
Lot 4cancelled

Denosumab (Osteoporosis) and Ferric Carboxymaltose

Award value

Start

01 Feb 2026

End

31 Jul 2027

Estimated

£27.4m

CPV

33600000
Lot 5cancelled

Apremilast

Award value

Start

01 Feb 2026

End

31 Oct 2027

Estimated

£1.5m

CPV

33600000
Lot 6cancelled

Cardiovascular and Respiratory Medicines

Award value

Start

01 Feb 2026

End

30 May 2028

Estimated

£457k

CPV

33600000
Lot 7cancelled

Nintedanib

Award value

Start

31 Mar 2026

End

30 May 2028

Estimated

£27.3m

CPV

33600000
Lot 8cancelled

Cancer Medicines (Group 1)

Award value

Start

01 Feb 2026

End

31 Jan 2027

Estimated

£15.2m

CPV

33600000
Lot 9cancelled

Cancer Medicines (Group 2)

Award value

Start

01 Feb 2026

End

31 Jan 2027

Estimated

£21.3m

CPV

33600000
Lot 10cancelled

Psychiatry and Neurology Medicines

Award value

Start

01 Feb 2026

End

30 Sept 2028

Estimated

£61k

CPV

33600000
Awarded to 2 suppliers